Harbour Investments Inc. Has $1.46 Million Position in Amgen Inc. $AMGN

Harbour Investments Inc. lowered its position in Amgen Inc. (NASDAQ:AMGN) by 0.9% in the second quarter, HoldingsChannel.com reports. The fund owned 5,221 shares of the medical research company’s stock after selling 48 shares during the quarter. Harbour Investments Inc.’s holdings in Amgen were worth $1,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in AMGN. Brighton Jones LLC lifted its stake in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Amgen by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 11,753 shares of the medical research company’s stock worth $3,662,000 after buying an additional 3,369 shares during the last quarter. Kingswood Wealth Advisors LLC lifted its stake in shares of Amgen by 2.3% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 3,524 shares of the medical research company’s stock worth $1,096,000 after buying an additional 79 shares during the last quarter. Johnson Investment Counsel Inc. lifted its stake in shares of Amgen by 0.8% during the 1st quarter. Johnson Investment Counsel Inc. now owns 25,689 shares of the medical research company’s stock worth $8,004,000 after buying an additional 197 shares during the last quarter. Finally, Boston Trust Walden Corp lifted its stake in shares of Amgen by 15.5% during the 1st quarter. Boston Trust Walden Corp now owns 44,520 shares of the medical research company’s stock worth $13,870,000 after buying an additional 5,983 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $298.81 on Friday. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $335.88. The firm has a market cap of $160.87 billion, a price-to-earnings ratio of 24.43, a P/E/G ratio of 2.61 and a beta of 0.49. The firm’s 50-day simple moving average is $287.14 and its 200 day simple moving average is $287.27.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the firm earned $4.97 EPS. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is currently 77.84%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.76% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

AMGN has been the subject of a number of research reports. UBS Group cut their target price on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research note on Wednesday, August 6th. Piper Sandler raised their target price on shares of Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research note on Monday, August 25th. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Bank of America raised their price target on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research report on Friday, September 26th. Finally, Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Seven analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus price target of $305.50.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.